CEO Kevin Kawchak founded the Physical AI clinical trial industry with the 2026 H. R. 9510 Bill, Phase I and Phase II LLM-Robotic pancreatic cancer trial protocols, and 25 supporting publications. Adaptions to ICH E6(R3), 21 CFR Part 50, and 21 CFR Part 312 modernized the regulation process using state of the art software (works are not endorsed or sponsored by ICH/CFR/FDA). 24 and 168 hour trial sponsor/trial site patient-robot simulations with hourly visualizations established automated AI processing at scale.
Several studies focused on the consistent performance of pancreatic cancer drug candidate: RAS(ON) inhibitor Daraxonrasib across proposals, simulations, verifications, and a 2030 hybrid surgery also utilized in the current Phase I robotic trial protocol. The Daraxonrasib articles prove AI utility for ongoing trials, and were conducted independently. Mr. Kawchak has also published 20 papers to establish LLM trial and cancer application trust, received U.S. Presidential recognition; and has research experience in cancer drug delivery devices.